Literature DB >> 18831915

Chemokines and bone remodeling.

E Galliera, M Locati, A Mantovani, M M Corsi.   

Abstract

Bone remodeling is characterized by spatial and temporal coupling of bone resorption and formation and is necessary for skeletal growth and normal bone structure maintenance. Imbalance of this process is related to metabolic bone disorders such as osteoporosis or rheumatoid arthritis. For this reason, bone remodeling is under the control of several local and systemic factors, including molecules of the immune system. The importance of the interplay of both the skeletal and immune systems is reflected by the emerging interdisciplinary research field, called osteoimmunology, focused on common aspects of osteology and immunology. This review focuses on the role of inflammatory mediators, such as cytokines in bone remodeling and, in particular, a subfamily of chemotactic cytokines or chemokines which are involved not only in several aspects of physiological bone remodeling but also in pathological bone disorders, such as rheumatoid arthritis or osteoporosis. Understanding the role of inflammation and chemokines will provide new insights for the treatment of diseases affecting both skeletal and immune systems, by the development of new therapeutic strategies targeting common inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831915     DOI: 10.1177/039463200802100301

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  9 in total

1.  Affective Disorders, Bone Metabolism, and Osteoporosis.

Authors:  Briana Mezuk
Journal:  Clin Rev Bone Miner Metab       Date:  2008-12

Review 2.  Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.

Authors:  Alan Sućur; Vedran Katavić; Tomislav Kelava; Zrinka Jajić; Natasa Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2014-06-10       Impact factor: 3.075

3.  Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.

Authors:  Alan Sucur; Zrinka Jajic; Marinko Artukovic; Marina Ikic Matijasevic; Branimir Anic; Darja Flegar; Antonio Markotic; Tomislav Kelava; Sanja Ivcevic; Natasa Kovacic; Vedran Katavic; Danka Grcevic
Journal:  Arthritis Res Ther       Date:  2017-06-15       Impact factor: 5.156

4.  Serum C-C Motif Ligand 11/eotaxin-1 May Serve as a Candidate Biomarker for Postmenopausal Osteoporosis.

Authors:  Wen Wang; Ci-You Huang; Zhuo-Ping Wang; Shan-Shan Xu; Tie-Yong Qian; Yi-Ding Chen; Wei-Guo Wu
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

Review 5.  Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Authors:  Zoltán Szekanecz; Hennie G Raterman; Zsófia Pethő; Willem F Lems
Journal:  Arthritis Res Ther       Date:  2019-01-10       Impact factor: 5.156

6.  Elevated plasma CXCL12/SDF-1 levels are linked with disease severity of postmenopausal osteoporosis.

Authors:  Xian-Wen Yang; Hong-Xing Huang; Fei Wang; Qi-Lin Zhou; Yan-Qiang Huang; Ru-Zi Qin
Journal:  Innate Immun       Date:  2019-10-22       Impact factor: 2.680

7.  Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells.

Authors:  Nihal AlMuraikhi; Nuha Almasoud; Sarah Binhamdan; Ghaydaa Younis; Dalia Ali; Muthurangan Manikandan; Radhakrishnan Vishnubalaji; Muhammad Atteya; Abdulaziz Siyal; Musaad Alfayez; Abdullah Aldahmash; Moustapha Kassem; Nehad M Alajez
Journal:  Stem Cells Int       Date:  2019-11-21       Impact factor: 5.443

8.  Stem Cell Fate and Immunomodulation Promote Bone Regeneration via Composite Bio-Oss®/AviteneTM Biomaterial.

Authors:  Maria Rosa Iaquinta; Fernanda Martini; Antonio D'Agostino; Lorenzo Trevisiol; Massimo Bersani; Elena Torreggiani; Mauro Tognon; John Charles Rotondo; Elisa Mazzoni
Journal:  Front Bioeng Biotechnol       Date:  2022-06-27

Review 9.  Metallothionein as an anti-inflammatory mediator.

Authors:  Ken-ichiro Inoue; Hirohisa Takano; Akinori Shimada; Masahiko Satoh
Journal:  Mediators Inflamm       Date:  2009-05-11       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.